🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
BIIB
NASDAQ
🇺🇸 US
Biogen Inc.
Pharmaceuticals
15Score
DipBuster Score™
$196.58
$2.09 (-1.05%)
Live price · Source: Yahoo
52-Week Position
$121.05
89% of range
$205.97
Beta
0.177
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.177
52W High$205.97
52W Low$121.05
🤖
Not a Dip — Score 15/100
Zone: Sell / Avoid
🔒 Unlock Pro
Valuation
P/E Ratio—
Mkt CapN/A
52W Position89% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.177
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️
Insider Buys
Track director & CEO open-market purchases
📊
Valuation Analysis
P/E, EV/EBITDA, DCF & NCAV metrics
📈
Financial Charts
Revenue, EBITDA, FCF & balance sheet trends
🤖
AI Analysis
Plain-English explanation of every key metric
Sign up free — charts & fundamentals included
Get financial charts, valuation data, dividends & news for Biogen Inc. free. Upgrade to Pro for insider signals & AI analysis.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
4/25
Momentum & Volume
6/25
Quality & Size
5/10
Insider Activity
0/10
Quick Take
⚪
Not a Dip
DipBuster Score: 15/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio include…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Christopher A. Viehbacher
Staff
7,605 employees
Website